Why Do Physicians Switch From One Antipsychotic Agent to Another?: The "Physician Drug Stereotype"
暂无分享,去创建一个
Michael Linden | R. Dittmann | M. Linden | J. Czekalla | Ralf W Dittmann | Lena Pyrkosch | Joerg Czekalla | L. Pyrkosch
[1] M Linden,et al. Therapeutic Standards in Psychopharmacology and Medical Decision-Making , 1994, Pharmacopsychiatry.
[2] R. Tamura,et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol , 1999, British Journal of Psychiatry.
[3] R. Dardennes,et al. Olanzapine for schizophrenia. , 2005, The Cochrane database of systematic reviews.
[4] Ronald R. Brown,et al. Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine , 2005, International clinical psychopharmacology.
[5] G. Tollefson,et al. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol , 1998, European Neuropsychopharmacology.
[6] G. Tollefson,et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial , 1996, Psychopharmacology.
[7] R. Tandon,et al. Efficacy of newer generation antipsychotics in the treatment of schizophrenia , 2003, Psychoneuroendocrinology.
[8] C. Beasley,et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial , 1997, European Neuropsychopharmacology.
[9] J. Ishigooka,et al. Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open‐label multicenter study in Japan , 2001, Psychiatry and clinical neurosciences.
[10] J. Lieberman,et al. Olanzapine versus haloperidol in the treatment of first episode psychosis , 1998, Schizophrenia Research.
[11] G. Tollefson,et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. , 1996, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[12] G. Tollefson,et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses , 1998, British Journal of Psychiatry.
[13] R. Tamura,et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.
[14] J. Calabrese,et al. Olanzapine Versus Placebo in Acute Mania: Treatment Responses in Subgroups , 2003, Journal of clinical psychopharmacology.
[15] G. Chapman,et al. Are More Options Always Better? , 1999, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] D. Kupfer,et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. , 2002, Archives of general psychiatry.
[17] G. Tollefson,et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. , 1997, Psychiatric services.
[18] G. Tollefson,et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. , 1997, The Journal of clinical psychiatry.
[19] S. Montgomery,et al. First clinical experience with olanzapine (LY 170053): results of an open‐label safety and dose‐ranging study in patients with schizophrenia , 1995, International clinical psychopharmacology.
[20] J. Peuskens. Clinical effectiveness in adults with chronic schizophrenia , 2004, European Neuropsychopharmacology.
[21] Philip Seeman,et al. Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.
[22] M. Tohen,et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. , 2000, Archives of general psychiatry.
[23] L. Yatham. Efficacy of Atypical Antipsychotics in Mood Disorders , 2003, Journal of clinical psychopharmacology.
[24] G. Tollefson,et al. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations , 1997, Schizophrenia Research.
[25] A. Cools,et al. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine , 1995, Psychopharmacology.
[26] M. Linden,et al. Therapist individuality in the diagnosis and treatment of depression. , 1993, Journal of affective disorders.
[27] Vimla L. Patel,et al. Emerging paradigms of cognition in medical decision-making , 2002, J. Biomed. Informatics.
[28] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[29] A. Fasoli. [Clinical decision analysis]. , 1986, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.
[30] A. Altamura,et al. Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. , 2004, Journal of clinical psychopharmacology.
[31] G. Tollefson,et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse , 2003, Journal of clinical psychopharmacology.
[32] G. Tollefson,et al. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. , 1997, American Journal of Psychiatry.
[33] G. Tollefson,et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. , 1997 .
[34] M. Linden. The role of the patient in treatment decisions. , 1997, Modern problems of pharmacopsychiatry.